|
1
|
Zhang J, Zhu Z, Liu Y, Jin X, Xu Z, Yu Q
and Li K: Diagnostic value of multiple tumor markers for patients
with esophageal carcinoma. PLoS One. 10:e01169512015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Y, Zhang YL, Chen HM, Pu HW, Ma WJ,
Li XM, Ma H and Chen X: Expression of Bmi-1 and PAI-1 in esophageal
squamous cell carcinoma. World J Gastroenterol. 20:5533–5539. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Crew KD and Neugut AI: Epidemiology of
upper gastrointestinal malignancies. Semin Oncol. 31:450–464. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vaupel P and Mayer A: Hypoxia in cancer:
Significance and impact on clinical outcome. Cancer Metastasis Rev.
26:225–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sudo T, Iwaya T, Nishida N, Sawada G,
Takahashi Y, Ishibashi M, Shibata K, Fujita H, Shirouzu K, Mori M
and Mimori K: Expression of mesenchymal markers vimentin and
fibronectin: The clinical significance in esophageal squamous cell
carcinoma. Ann Surg Oncol. 20 Suppl 3:S324–S335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Song LB, Zeng MS, Liao WT, Zhang L, Mo HY,
Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, et al: Bmi-1 is a novel
molecular marker of nasopharyngeal carcinoma progression and
immortalizes primary human nasopharyngeal epithelial cells. Cancer
Res. 66:6225–6232. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van der Lugt NM, Domen J, Linders K, van
Roon M, Robanus-Maandag E, te Riele H, van der Valk M, Deschamps J,
Sofroniew M, van Lohuizen M, et al: Posterior transformation,
neurological abnormalities, and severe hematopoietic defects in
mice with a targeted deletion of the bmi-1 proto-oncogene. Genes
Dev. 8:757–769. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jacobs JJ, Kieboom K, Marino S, DePinho RA
and van Lohuizen M: The oncogene and Polycomb-group gene bmi-1
regulates cell proliferation and senescence through the ink4a
locus. Nature. 397:164–168. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu YW, Li J and Guo WJ: Expression and
clinicopathological significance of Mel-18 and Bmi-1 mRNA in
gastric carcinoma. J Exp Clin Cancer Res. 29:1432010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo BH, Feng Y, Zhang R, Xu LH, Li MZ,
Kung HF, Song LB and Zeng MS: Bmi-1 promotes invasion and
metastasis, and its elevated expression is correlated with an
advanced stage of breast cancer. Mol Cancer. 10:102011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tao J, Liu YL, Zhang G, Ma YY, Cui BB and
Yang YM: Expression and clinicopathological significance of Mel-18
mRNA in colorectal cancer. Tumour Biol. 35:9619–9625. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dalley AJ, Pitty LP, Major AG, Abdulmajeed
AA and Farah CS: Expression of ABCG2 and Bmi-1 in oral potentially
malignant lesions and oral squamous cell carcinoma. Cancer Med.
3:273–283. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li DW, Tang HM, Fan JW, Yan DW, Zhou CZ,
Li SX, Wang XL and Peng ZH: Expression level of Bmi-1 oncoprotein
is associated with progression and prognosis in colon cancer. J
Cancer Res Clin Oncol. 136:997–1006. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guo P, Gao A, Zhang G, Han H and Zhou Q:
Decoding the knots of initiation of oncogenic
epithelial-mesenchymal transition in tumor progression. Curr Cancer
Drug Targets. 13:996–1011. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vonlanthen S, Heighway J, Altermatt HJ,
Gugger M, Kappeler A, Borner MM, van Lohuizen M and Betticher DC:
The bmi-1 oncoprotein is differentially expressed in non-small cell
lung cancer and correlates with INK4A-ARF locus expression. Br J
Cancer. 84:1372–1376. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hagiwara T, Nakashima K, Hirano H, Senshu
T and Yamada M: Deimination of arginine residues in
nucleophosmin/B23 and histones in HL-60 granulocytes. Biochem
Biophys Res Commun. 290:979–983. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang X and Han J: Expression of
peptidylarginine deiminase type 4 (PAD4) in various tumors. Mol
Carcinog. 45:183–196. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakashima K, Arai S, Suzuki A, Nariai Y,
Urano T, Nakayama M, Ohara O, Yamamura K, Yamamoto K and Miyazaki
T: PAD4 regulates proliferation of multipotent haematopoietic cells
by controlling c-myc expression. Nat Commun. 4:18362013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang X, Han J, Pang L, Zhao Y, Yang Y and
Shen Z: Increased PADI4 expression in blood and tissues of patients
with malignant tumors. BMC Cancer. 9:402009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tanikawa C, Espinosa M, Suzuki A, Masuda
K, Yamamoto K, Tsuchiya E, Ueda K, Daigo Y, Nakamura Y and Matsuda
K: Regulation of histone modification and chromatin structure by
the p53-PADI4 pathway. Nat Commun. 3:6762012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ERICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang XW, Sheng YP, Li Q, Qin W, Lu YW,
Cheng YF, Liu BY, Zhang FC, Li J, Dimri GP and Guo WJ: BMI1 and
Mel-18 oppositely regulate carcinogenesis and progression of
gastric cancer. Mol Cancer. 9:402010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu WL, Guo XZ, Zhang LJ, Wang JY, Zhang
G, Guan S, Chen YM, Kong QL, Xu LH, Li MZ, et al: Prognostic
relevance of Bmi-1 expression and autoantibodies in esophageal
squamous cell carcinoma. BMC Cancer. 10:4672010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qin ZK, Yang JA, Ye YL, Zhang X, Xu LH,
Zhou FJ, Han H, Liu ZW, Song LB and Zeng MS: Expression of Bmi-1 is
a prognostic marker in bladder cancer. BMC Cancer. 9:612009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang X, Gamble MJ, Stadler S, Cherrington
BD, Causey CP, Thompson PR, Roberson MS, Kraus WL and Coonrod SA:
Genome-wide analysis reveals PADI4 cooperates with Elk-1 to
activate c-Fos expression in breast cancer cells. PLoS Genet.
7:e10021122011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Christophorou MA, Castelo-Branco G,
Halley-Stott RP, Oliveira CS, Loos R, Radzisheuskaya A, Mowen KA,
Bertone P, Silva JC, Zernicka-Goetz M, et al: Citrullination
regulates pluripotency and histone H1 binding to chromatin. Nature.
507:104–108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cui YY, Yan L, Zhou J, Zhao S, Zheng YB,
Sun BH, Lv HT, Rong FN and Chang XT: The role of peptidylarginine
deiminase 4 in ovarian cancer cell tumorigenesis and invasion.
Tumour Biol. 37:5375–5383. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tanikawa C, Espinosa M, Suzuki A, Masuda
K, Yamamoto K, Tsuchiya E, Ueda K, Daigo Y, Nakamura Y and Matsuda
K: Regulation of histone modification and chromatin structure by
the p53-PADI4 pathway. Nat Commun. 3:6762012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kolodziej S, Kuvardina ON, Oellerich T,
Herglotz J, Backert I, Kohrs N, Buscató El, Wittmann SK,
Salinas-Riester G, Bonig H, et al: PADI4 acts as a coactivator of
Tal1 by counteracting repressive histone arginine methylation. Nat
Commun. 5:39952014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cuthbert GL, Daujat S, Snowden AW,
Erdjument-Bromage H, Hagiwara T, Yamada M, Schneider R, Gregory PD,
Tempst P, Bannister AJ and Kouzarides T: Histone deimination
antagonizes arginine methylation. Cell. 118:545–553. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Y, Wysocka J, Sayegh J, Lee YH,
Perlin JR, Leonelli L, Sonbuchner LS, McDonald CH, Cook RG, Dou Y,
et al: Human PAD4 regulates histone arginine methylation levels via
demethylimination. Science. 306:279–283. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Slack JL, Causey CP and Thompson PR:
Protein arginine deiminase 4: A target for an epigenetic cancer
therapy. Cell Mol Life Sci. 68:709–720. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chang X, Hou X, Pan J, Fang K, Wang L and
Han J: Investigating the pathogenic role of PADI4 in oesophageal
cancer. Int J Biol Sci. 7:769–781. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hashiguchi Y, Tsuda H, Yamamoto K, Inoue
T, Ishiko O and Ogita S: Combined analysis of p53 and RB pathways
in epithelial ovarian cancer. HUM Pathol. 32:988–996. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lindström MS, Klangby U and Wiman KG:
p14ARF homozygous deletion or MDM2 overexpression in Burkitt
lymphoma lines carrying wild type p53. Oncogene. 20:2171–2177.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ichimura K, Bolin MB, Goike HM, Schmidt
EE, Moshref A and Collins VP: Deregulation of the p14ARF/Mdm2/p53
pathways is a prerequisite for human astrocytic gliomas with G1-S
transition control gene abnormalities. Cancer Res. 60:417–424.
2000.PubMed/NCBI
|
|
39
|
Shafaroudi AM, Mowla SJ, Ziaee SA, Bahrami
AR, Atlasi Y and Malakootian M: Overexpression of BMI1, a polycomb
group repressor protein, in bladder tumors: A preliminary report.
Urol J. 5:99–105. 2008.PubMed/NCBI
|
|
40
|
Taran K, Wysocka A, Sitkiewicz A, Kobos J
and Andrzejewska E: Evaluation of potential prognostic value of
Bmi-1 gene product and selected markers of proliferation (Ki-67)
and apoptosis (p53) in the neuroblastoma group of tumors. Postepy
Hig Med Dosw (Online). 70:110–116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Beà S, Tort F, Pinyol M, Puig X, Hernández
L, Hernández S, Fernandez PL, van Lohuizen M, Colomer D and Campo
E: BMI-1 gene amplification and overexpression in hematological
malignancies occur mainly in mantle cell lymphomas. Cancer Res.
61:2409–2412. 2001.PubMed/NCBI
|
|
42
|
Yao D, Wang Y, Xue L, Wang H, Zhang J and
Zhang X: Different expression pattern and significance of
p14ARF-Mdm2-p53 pathway and Bmi-1 exist between gastric cardia and
distal gastric adenocarcinoma. Hum Pathol. 44:844–851. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tanikawa C, Ueda K, Nakagawa H, Yoshida N,
Nakamura Y and Matsuda K: Regulation of protein Citrullination
through p53/PADI4 network in DNA damage response. Cancer Res.
69:8761–8769. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li P, Yao H, Zhang Z, Li M, Luo Y,
Thompson PR, Gilmour DS and Wang Y: Regulation of p53 target gene
expression by peptidylarginine deiminase 4. Mol Cell Biol.
28:4745–4758. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yao H, Li P, Venters BJ, Zheng S, Thompson
PR, Pugh BF and Wang Y: Histone Arg modifications and p53 regulate
the expression of OKL38, a mediator of apoptosis. J Biol Chem.
283:20060–20068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lda C Braga, Silva LM, Piedade JB, Traiman
P and da Silva Filho AL: Epigenetic and expression analysis of
TRAIL-R2 and BCL2: On the TRAIL to knowledge of apoptosis in
ovarian tumors. Arch Gynecol Obstet. 289:1061–1069. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pavelic S Kraljevic, Cacev T and Kralj M:
A dual role of p21waf1/cip1 gene in apoptosis of HEp-2 treated with
cisplatin or methotrexate. Cancer Gene Ther. 15:576–590. 2008.
View Article : Google Scholar : PubMed/NCBI
|
